ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Taro Pharmaceutical Industries Ltd. (TARO) Report Updated: Nov 24, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Taro Pharmaceutical Industries Ltd. (TARO)

Rating: Strong Buy Volatility: Moderate
Total Grade: A Industry: Pharmaceuticals
Competitors: ANIP, SCLN, HSP, AVNR

Stock Analysis

Rating: Monthly View

A
B
C
D
F
November December January February March April May June July August September October

Rating: Weekly View

This Week: A down upgrade
Last Week: B same downgrade
Two Weeks Ago: A up no change
service keys

Taro Pharmaceutical Industries Ltd.© quotemedia

Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, together with its subsidiaries, engages in the research, development, production, and marketing of pharmaceutical products primarily in the United States, Canada, and Israel. It offers prescription and over-the-counter (OTC) pharmaceutical products focusing on primary areas comprising topical creams and ointments, liquids, capsules, and tablets principally in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company also develops and manufactures active pharmaceutical ingredients for use in its finished dosage form products. Taro Pharmaceutical Industries sells and distributes its products to drug industry wholesalers, drug distributors, drug store chains, food stores, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Sun Pharmaceutical Industries Ltd.

Recent News: Taro Pharmaceutical Industries Ltd.